F. Cardenal

Anti-Hu antibodies in patients with small-cell lung cancer: association with complete response to therapy and improved survival.

Francesc Graus, J Dalmou, R. Reñé et al. · Journal of Clinical Oncology · 1997 · 377 citations

Medicine, Neurology, Oncology +17

A multicenter international randomized phase III study comparing cisplatin in combination with irinotecan or etoposide in previously untreated small-cell lung cancer patients with extensive disease

Petr Zatloukal, F. Cardenal, A. Szczęsna et al. · Annals of Oncology · 2010 · 150 citations · Full text

Medicine, Oncology, Pharmacology +13

Serum Anti-p53 Antibodies and Prognosis of Patients With Small-Cell Lung Cancer

Myrna R. Rosenfeld, Laura Schramm, J. B. Posner et al. · JNCI Journal of the National Cancer Institute · 1997 · 56 citations · Full text

Medicine, Oncology, Chemotherapy +14

Single nucleotide polymorphisms in MDR1 gen correlates with outcome in advanced non-small-cell lung cancer patients treated with cisplatin plus vinorelbine

Núria Viñolas, Mariano Provencio, Noemı́ Reguart et al. · Lung Cancer · 2010 · 45 citations · Full text

Medicine, Genetics, Oncology +14

A randomized phase II study comparing induction or consolidation chemotherapy with cisplatin–docetaxel, plus radical concurrent chemoradiotherapy with cisplatin–docetaxel, in patients with unresectable locally advanced non-small-cell lung cancer

Suresh Senan, F. Cardenal, Johan Vansteenkiste et al. · Annals of Oncology · 2010 · 35 citations · Full text

Medicine, Oncology, Pharmacotherapy +16